POS-350. Finerenone in mild to severe chronic kidney disease and type 2 diabetes: The fidelity prespecified pooled analysis

Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) have a residual risk of CKD progression despite current therapies, which tends to worsen with more advanced CKD. Finerenone, a novel, selective, nonsteroidal mineralocorticoid receptor antagonist, decreased the risk of kidney and cardiovascular (CV) outcomes in phase III trials for patients with CKD and T2D. Combining finerenone with other CKD in T2D therapies, such as sodium-glucose co-transporter-2 inhibitors (SGLT-2is) is of interest, but more data are needed. FI nerenone in chronic kiD ney diseasE and type 2 diabetes: Combined FIDEL IO-DKD and FI GARO-DKD T rial programme analY sis (FIDELITY) aims to evaluate the effects of finerenone on composite kidney and CV endpoints in varying stages of CKD (defined by estimated glomerular filtration rate [eGFR] and urine albumin-to-creatinine ratio [UACR]). The benefits of combining finerenone with SGLT-2is was also evaluated.Sin financiación6.234 JCR (2021) Q1, 13/90 Urology & Nephrology1.239 SJR (2021) Q1, 12/72 NephrologyNo data IDR 2021UE